Insights Into Diffuse Large B-Cell Lymphoma (DLBCL)
Perspectives on treatment decision-making in DLBCL, including first-line and relapsed/refractory approaches, referral patterns across care settings, and factors influencing clinical decision-making.
Central – March 28, 2026
Faculty Co-Chair
Tara M. Graff, DO
Mission Cancer + Blood, Des Moines, IA, USA
Faculty Co-Chair
Matthew Lunning, DO
University of Nebraska Medical Center, Omaha, USA
Southeast – April 17, 2026
Faculty Chair
Amitkumar Mehta, MD
University of Alabama at Birmingham, USA
Insights Obtained From
- Missouri, Texas
Insights Obtained From
- Georgia, North Carolina, Tennessee
REPORT SNAPSHOT
- Initial treatment of DLBCL and current first-line data
- Treatment of relapsed/refractory DLBCL
- Detailed insights and attendee takeaways
- ARS data
GEOGRAPHIC REPRESENTATION AND CONTENT DEVELOPMENT
- Data collection was accomplished through the use of audience response system questioning and moderated discussion
- The group of experts comprised 10–15 community oncologists representative of each region
Purchase Report
Thank you for your interest in our insights.
Complete the form below to receive additional information.